Gain Therapeutics, Inc. (GANX)
NASDAQ: GANX · Real-Time Price · USD
1.850
-0.100 (-5.13%)
At close: Apr 28, 2026, 4:00 PM EDT
1.880
+0.030 (1.62%)
After-hours: Apr 28, 2026, 5:19 PM EDT
Gain Therapeutics Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Gain Therapeutics stock have an average target of 7.50, with a low estimate of 6.00 and a high estimate of 9.00. The average target predicts an increase of 305.41% from the current stock price of 1.85.
Analyst Consensus: Strong Buy
* Price targets were last updated on Dec 19, 2025.
Analyst Ratings
The average analyst rating for Gain Therapeutics stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 | 5 | 4 |
| Buy | 1 | 1 | 1 | 1 | 1 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 6 | 6 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $8 | Strong Buy | Reiterates | $8 | +332.43% | Dec 19, 2025 |
| BTIG | BTIG | Strong Buy Reiterates $9 | Strong Buy | Reiterates | $9 | +386.49% | Oct 15, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $8 | Strong Buy | Reiterates | $8 | +332.43% | Oct 13, 2025 |
| Maxim Group | Maxim Group | Strong Buy Maintains $5 → $7 | Strong Buy | Maintains | $5 → $7 | +278.38% | Oct 7, 2025 |
| BTIG | BTIG | Strong Buy Reiterates $9 | Strong Buy | Reiterates | $9 | +386.49% | Sep 8, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-0.62
from -0.61
EPS Next Year
-0.65
from -0.62
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | n/a | n/a | ||||||
| Avg | n/a | n/a | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -0.53 | -0.49 | |
| Avg | -0.62 | -0.65 | |
| Low | -0.77 | -0.73 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.